GM-CSF can improve the efficacy of immunotherapy of CLL [60] as well as enhances CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) and R-CHOP (Rituximab + CHOP) treatment in mouse model of DLBCL [61]. Here, CSF2 is linked to B-cell chronic lymphocytic leukemia.